Biotech & Bioprocessing

In the high-stakes world of biopharmaceutical manufacturing, where a single production run can be valued in the millions of dollars, the quiet disposal of a failed batch represents a catastrophic loss of resources, time, and patient trust. While the industry strives for perfection, the reality is

The body's intricate system for manufacturing blood cells is a marvel of biological engineering, but when this internal factory fails, the consequences are catastrophic, leaving patients defenseless against infection and uncontrolled bleeding. For individuals diagnosed with severe aplastic anemia

Imagine a landscape where a rare cancer, often resistant to repeated treatments, finally meets a game-changing solution. On December 4, this became reality as the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel, marketed as Breyanzi by Juno Therapeutics, as the first

What if a hidden enemy within the body, silently damaging vital organs, could finally be dismantled with precision? For thousands battling rare diseases like AL amyloidosis, where toxic protein deposits wreak havoc on the heart and kidneys, this prospect is no longer a distant dream. A

Picture a medical landscape where treatments can slip past the body's toughest defenses, delivering healing payloads directly to diseased cells without harming the surrounding healthy tissue. This isn't science fiction but the tantalizing promise of engineered exosomes—tiny biological couriers that

Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology